Estimation of the long-term cardiovascular events using ukpds risk engine in metabolic syndrome patients

Indian Journal of Pharmaceutical Sciences

Volumn 76, Issue 2, 2014, Pages 174-178

  Shivakumar, V ^a   Kandhare, A D ^a   Rajmane, A R ^a   Adil, M ^a   Ghosh, P ^a   Badgujar, L B ^b   Saraf, M N ^b   Bodhankar, S L ^a  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

^b BOMBAY COLLEGE OF PHARMACY   (India)

Author keywords

cardiovascular complications; metabolic syndrome; UKPDS risk engine

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT TOOL; DISEASE ASSOCIATION; ETHNIC GROUP; HUMAN; INDIA; ISCHEMIC HEART DISEASE; MEDICAL RECORD; METABOLIC SYNDROME X; PHYSICIAN; PREDICTION; RISK ASSESSMENT; STRUCTURED INTERVIEW; UNITED KINGDOM PROSPECTIVE DIABETES STUDY RISK ENGINE;

EID: 84899695406     PISSN: 0250474X     EISSN: 19983743     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Ghosh P, Kandhare AD, Raygude KS, Kumar VS, Rajmane AR, Adil M, et al. Determination of the long term diabetes related complications and cardiovascular events using UKPDS risk engine and UKPDS outcomes model in a representative western Indian population. Asian Pac J Trop Dis 2012;2:S642-50.
2. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 1992;41:715-22.
3. Kandhare AD, Bodhankar SL, Singh V, Mohan V, Thakurdesai PA. Antiasthmatic effects of type-A procyanidine polyphenols from cinnamon bark in ovalbumin-induced airway hyperresponsiveness in laboratory animals. Biomed Aging Pathol 2013;3:23-30.
4. Patil MV, Kandhare AD, Bhise SD. Antiarthritic and antiinflammatory activity of Xanthium srtumarium L. ethanolic extract in Freund's complete adjuvant induced arthritis. Biomed Aging Pathol 2012;2:6-15.
5. Reaven G. Metabolic syndrome pathophysiology and implications for management of cardiovascular disease. Circulation 2002;106:286-8.
6. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
7. Visnagri A, Kandhare AD, Shiva Kumar V, Rajmane AR, Mohammad A, Ghosh P, et al. Elucidation of ameliorative effect of Co-enzyme Q10 in streptozotocin-induced diabetic neuropathic perturbation by modulation of electrophysiological, biochemical and behavioral markers. Biomed Aging Pathol 2012;2:157-72.
8. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Bonadonna RC, et al. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome prospective data from the Bruneck Study. Diabetes Care 2003;26:1251-7.
9. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the US. Diabetes Care 2005;28:2745-9.
10. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9.
11. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. J Am Med Assoc 2002;288:2709-16.
12. Resnick HE, Jones K, Ruotolo G, Jain AK, Henderson J, Lu W, et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians the Strong Heart Study. Diabetes Care 2003;26:861-7.
13. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB Sr, Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004;110:380-5.
14. Visnagri A, Kandhare AD, Chakravarty S, Ghosh P, Bodhankar SL. Hesperidin, a flavanoglycone attenuates experimental diabetic neuropathy via modulation of cellular and biochemical marker to improve nerve functions. Pharm Biol 2014 DOI: 10.3109/13880209.2013.870584.
15. Visnagri A, Kandhare AD, Ghosh P, Bodhankar SL. Endothelin receptor blocker bosentan inhibits hypertensive cardiac fibrosis in pressure overload-induced cardiac hypertrophy in rats. Cardiovasc Endocrinol 2013;2:85-97.
16. Stern MP, Williams K, González-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004;27:2676-81.
17. McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005;28:385-90.
18. Alberti KG, Zimmet P. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
19. Alberti K, Zimmet P, Shaw J. The metabolic syndrome: A new worldwide definition. Lancet 2005;366:1059.
20. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005;112:2735-52.
21. Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Nilsson PM, Gudbjörnsdottir S. Risk Prediction of Cardiovascular Disease in Type 2 Diabetes A risk equation from the Swedish National Diabetes Register. Diabetes Care 2008;31:2038-43.
22. Chamnan P, Simmons R, Sharp S, Griffin S, Wareham N. Cardiovascular risk assessment scores for people with diabetes: A systematic review. Diabetologia 2009;52:2001-14.
23. Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HA, et al. UKPDS 60 risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002;33:1776-81.
24. Stephens JW, Ambler G, Vallance P, Betteridge DJ, Humphries SE, Hurel SJ. Cardiovascular risk and diabetes. Are the methods of risk prediction satisfactory? Eur J Cardiovasc Prev Rehabil 2004;11:521-8.
25. Yang X, So WY, Kong AP, Ma RC, Ko GT, Ho CS, et al. Development and validation of a total coronary heart disease risk score in type 2 diabetes mellitus. Am J Cardiol 2008;101:596-601.
26. Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman R. The UKPDS risk engine: A model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci 2001;101:671-9.
27. Kamble H, Kandhare AD, Bodhankar S, Mohan V, Thakurdesai P. Effect of low molecular weight galactomannans from fenugreek seeds on animal models of diabetes mellitus. Biomed Aging Pathol 2013;3:145-51.
28. Patil MV, Kandhare AD, Ghosh P, Bhise SD. Determination of role of GABA and nitric oxide in anticonvulsant activity of Fragaria vesca L. ethanolic extract in chemically induced epilepsy in laboratory animals. Orient Pharm Exp Med 2012;12:255-64.
29. Ravikiran M, Bhansali A, Ravikumar P, Bhansali S, Dutta P, Thakur J, et al. Prevalence and risk factors of metabolic syndrome among Asian Indians: A community survey. Diabetes Res Clin Pract 2010;89:181-8.
30. Gupta R, Deedwania PC, Gupta A, Rastogi S, Panwar RB, Kothari K. Prevalence of metabolic syndrome in an Indian urban population. Int J Cardiol 2004;97:257-61.
31. Tan CE, Ma S, Wai D, Chew SK, Tai ES. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care 2004;27:1182-6.
32. Simmons RK, Coleman RL, Price HC, Holman RR, Khaw KT, Wareham NJ, et al. Performance of the UK prospective diabetes study risk engine and the Framingham risk equations in estimating cardiovascular disease in the EPIC-Norfolk cohort. Diabetes Care 2009;32:708-13.
33. Misra A, Pandey R, Devi JR, Sharma R, Vikram N, Khanna N. High prevalence of diabetes, obesity and dyslipidaemia in urban slum population in northern India. Int J Obes Relat Metab Disord 2001;25:1722.